Literature DB >> 15569108

Meta-analysis: the detection of pancreatic malignancy with positron emission tomography.

L A Orlando1, S L Kulasingam, D B Matchar.   

Abstract

BACKGROUND: Several factors contribute to the high mortality of pancreatic cancer, including limitations of diagnostic imaging. AIM: To perform a meta-analysis to assess the diagnostic accuracy of Fluro-deoxy-glucose positron emission tomography with computed tomography compared with computed tomography alone.
METHODS: Articles were identified through a MEDLINE search and bibliography review. Summary estimates and receiver operating curves were calculated using Meta-Test 0.6. Publication bias and heterogeneity were assessed with a funnel plot and chi-squared test.
RESULTS: The summary estimate and 95% confidence interval for sensitivity and specificity were as follows: computed tomography 81% (72-88%) and 66% (53-77%), PET after a positive computed tomography 92% (87-95%) and 68% (51-81%), PET after a negative computed tomography 73% (50-88%) and 86% (75-93%) and PET after an indeterminate computed tomography 100 and 68%. The area under the summary receiver operating curve was 0.82 for computed tomography and 0.94 for PET. There was no heterogeneity or publication bias.
CONCLUSIONS: Our results suggest that although adding Fluro-deoxy-glucose positron emission tomography to the diagnostic work-up may enhance the diagnosis of pancreatic malignancy, its usefulness will vary depending upon the pretest probability of the patient, the results of computed tomography and the provider's testing thresholds. Further evaluation using a well-designed prospective study with a cost-effectiveness analysis is needed to clarify the appropriate role of Fluro-deoxy-glucose positron emission tomography.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569108     DOI: 10.1111/j.1365-2036.2004.02266.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.

Authors:  Tong Dai; Elizabeta Popa; Manish A Shah
Journal:  Curr Treat Options Oncol       Date:  2014-09

2.  Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.

Authors:  Rathan M Subramaniam; Anthony F Shields; Archana Sachedina; Lucy Hanna; Fenghai Duan; Barry A Siegel; Bruce E Hillner
Journal:  Oncologist       Date:  2016-07-08

3.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

4.  Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.

Authors:  Berit Velstra; Marieke A Vonk; Bert A Bonsing; Bart J Mertens; Simone Nicolardi; Anouck Huijbers; Hans Vasen; André M Deelder; Wilma E Mesker; Yuri E M van der Burgt; Rob A E M Tollenaar
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-21       Impact factor: 4.553

5.  Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.

Authors:  Erkan Topkan; Cem Parlak; Ayşe Kotek; Ali Fuat Yapar; Berrin Pehlivan
Journal:  BMC Gastroenterol       Date:  2011-11-10       Impact factor: 3.067

6.  Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma.

Authors:  Erkan Topkan; Ali A Yavuz; Mehmet Aydin; Cem Onal; Fuat Yapar; Melek N Yavuz
Journal:  J Exp Clin Cancer Res       Date:  2008-09-23

Review 7.  Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications.

Authors:  John Chang; Donald Schomer; Tomislav Dragovich
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

8.  PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study.

Authors:  Entesar Dalah; An Tai; Kiyoko Oshima; William A Hall; Beth Erickson; X Allen Li
Journal:  Transl Oncol       Date:  2018-07-17       Impact factor: 4.243

Review 9.  Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Thomas T Poels; Floris A Vuijk; Lioe-Fee de Geus-Oei; Alexander L Vahrmeijer; Daniela E Oprea-Lager; Rutger-Jan Swijnenburg
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.